Clinical Trial: Open Label, 6-month Study for High Frequency and Chronic Migraine,
Study Status: Completed
Recruit Status: RECRUITING
Condition: Chronic Migraine, Headache
Study Type: OBSERVATIONAL
Official Title: A Multi-Center Unblinded Proof-of-Concept Study of DaxibotulinumtoxinA for Migraine Prevention in High-Frequency and Chronic Migraine: the Standard Paradigm
Brief Summary:
This is a prospective, multi-center, unblinded study in patients with migraine (? 8 MMDs/month) requiring preventive treatment.Enrolled patients will receive DAX administered subcutaneously using an established, published, legacy injection paradigm (referred to herein as the "standard paradigm").The safety and efficacy outcome measures will be assessed at selected dosing segments during the 24-week treatment phase.
Read more